ArticleMedicine2026
Association of an age-albumin-red cell distribution width score with 28-day in-hospital mortality in emergency department patients with suspected sepsis: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the performance of a simple age-albumin-red cell distribution width (AAR) score for stratifying 28-day in-hospital mortality risk in an operational cohort of adult emergency department (ED) patients with suspected sepsis and in a later-period subgroup. This single-center retrospective cohort study analyzed an operational ED suspected-sepsis cohort of 852 adults defined by a modified early warning score of 5 or higher plus an infection-related ED discharge diagnosis from 2022 to 2025. The AAR score assigned one point each for age ≥ 75 years, albumin < 3.0 g/dL, and red cell distribution width ≥ 14.5%; scores ≥ 2 indicated high risk. Performance was assessed using the area under the receiver operating characteristic curve (AUROC), classification metrics, calibration, and exploratory clinical net benefit overall and across chronological study periods. Overall, 98 patients (11.5%) died within 28 days. The AAR AUROC was 0.787 (95% confidence interval [CI]: 0.740-0.833) overall and 0.778 (95% CI: 0.703-0.852) in 2024 to 2025; paired comparison did not demonstrate greater discrimination than continuous albumin alone (difference, 0.013; 95% CI: -0.074-0.100; P = .770). However, mortality increased stepwise across AAR categories (2.2%, 7.4%, 21.7%, and 49.2%), and this gradient was preserved in the later-period cohort (1.4%, 6.6%, 15.9%, and 41.4%). The earlier-period equation overpredicted absolute mortality risk in the later period. The AAR score combined 3 routinely available variables into 4 ordinal groups with a consistent mortality gradient across study periods. Its simple 0 to 3-point structure supports further external evaluation as an adjunct to early ED risk stratification. Patient-level probability estimation and decision-support use require additional validation and recalibration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.